Disease · MONDO_0011655

alveolar soft part sarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. alveolar soft part sarcoma. Diseases, record MONDO_0011655. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011655

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: alveolar soft part sarcoma; Open Targets
Open Targets ID: MONDO_0011655; Open Targets
Other names: ASPS, adult alveolar soft Part sarcoma, alveolar soft part sarcoma (disease); Open Targets
Disease Ontology: DOID:4239; Disease Ontology
MeSH: D018234; MeSH
NCI Thesaurus: C3750; NCI Thesaurus
NCI Thesaurus: C7943; NCI Thesaurus
Orphanet: ORPHA:163699; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 32 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs32

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 3	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
CEDIRANIB	CHEMBL491473	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
SELINEXOR	CHEMBL3545185	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RIVOCERANIB	CHEMBL3186534	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SUNITINIB	CHEMBL535	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
APL-501	CHEMBL4594355		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AXITINIB	CHEMBL1289926	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BENMELSTOBART	CHEMBL5315042	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 32

See all 32 drugs

Targets77

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
ADRM1	26S proteasome	1	26S proteasome inhibitor	Phase 1	https://conductscience.org/library/genes/11047	Drugs and targets

1 to 10 of 77

See all 77 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00642941	A Study of R1507 in Participants With Recurrent or Refractory Sarcoma	Phase 2	317	2021-02-03	Sarcoma	TEPROTUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02815995	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	Phase 2	57	2025-06-12	Advanced and/or Metastatic Sarcoma	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00942877	Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma	Phase 2	53	2021-04-27	Sarcoma, Alveolar Soft Part	CEDIRANIB	Its record names the disease	ClinicalTrials.gov
NCT00385203	The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).	Phase 2	35	2012-07-16	Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas	CEDIRANIB	Its record names the disease	ClinicalTrials.gov
NCT01391962	Sunitinib or Cediranib for Alveolar Soft Part Sarcoma	Phase 2	34	2024-09-19	Sarcoma, Alveolar Soft Part	CEDIRANIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02636725	Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas	Phase 2	33	2021-11-26	Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas	AXITINIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03016819	Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)	Phase 3	325		Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma	CATEQUENTINIB	Its record names the disease	ClinicalTrials.gov
NCT03277924	Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas	Phase 1/2	197		Soft Tissue Sarcoma, Bone Sarcoma	CISPLATIN, DACARBAZINE, DOXORUBICIN, EPIRUBICIN, IFOSFAMIDE, METHOTREXATE, NIVOLUMAB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00401388	A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas	Phase 2	72		Chondrosarcomas, Alveolar Soft Part Sarcomas, Extra Skeletal Myxoid Chondrosarcomas	PERIFOSINE	Its record names the disease	ClinicalTrials.gov
NCT03141684	Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma	Phase 2	63		Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma	ATEZOLIZUMAB, BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AZD2171 (Cediranib) 30 mg vs Sunitinib Malate 37.5 mg: deaths from any cause	0 of 29	1 of 27	56	NCT01391962	Trial comparisons
AZD2171 (Cediranib) 30 mg vs Sunitinib Malate 37.5 mg: serious adverse events	7 of 29	7 of 27	56	NCT01391962	Trial comparisons
Adult Participants w/Alveolar Soft Part Sarcoma vs Pediatric Participants w/Alveolar Soft Part Sarcoma: Number of Participants With Serious and Non-serious Adverse Events	45 of 46	7 of 7	53	NCT00942877	Trial comparisons
Adult Participants w/Alveolar Soft Part Sarcoma vs Pediatric Participants w/Alveolar Soft Part Sarcoma: deaths from any cause	2 of 46	0 of 7	53	NCT00942877	Trial comparisons
Adult Participants w/Alveolar Soft Part Sarcoma vs Pediatric Participants w/Alveolar Soft Part Sarcoma: serious adverse events	22 of 46	6 of 7	53	NCT00942877	Trial comparisons
Cediranib 45 mg/Day GIST vs Cediranib 45 mg/Day STS: Objective Tumour Response, Investigator Review	0 of 24	4 of 10	34	NCT00385203	Trial comparisons
Cediranib 45 mg/Day GIST vs Cediranib 45 mg/Day STS: serious adverse events	10 of 24	3 of 10	34	NCT00385203	Trial comparisons

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36302173	RESULT	1	PubMed
31078463	RESULT	1	PubMed
42051923	DERIVED	1	PubMed
41999612	DERIVED	1	PubMed
41836677	DERIVED	1	PubMed
41559089	DERIVED	1	PubMed
39356980	DERIVED	1	PubMed
37672694	DERIVED	1	PubMed
36267741	DERIVED	1	PubMed
35934010	DERIVED	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011655

GET https://conductscience.org/api/diseases/v1/MONDO_0011655/drugs?page=2

API reference For AI assistants